`

ALX Oncology

Biotechnology Research

Specialities :
Immuno-oncology
Novel biologics
Research and development
Innovation
And cd47
revenue-icon Revenue
11M - 100M
funding-icon Total Funding
$63.2M
size-icon Size
51 - 200

Frequently Asked Questions About ALX Oncology

What does Alx oncology do?+

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncologys lead product candidate, evorpacept (also known as ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents

What are Alx oncology's specialties? +

Immuno-oncology,novel biologics,research and development,innovation,and cd47

What is Alx oncology's industry? +

Alx oncology operates in the Biotechnology research industry.

What is Alx oncology's revenue? +

Alx oncology's revenue is 11m - 100m

What is Alx oncology's company size? +

Alx oncology has 51 - 200 employees.

The Go-to Sales Technology According to G2

G2 Badges Map
Get Started With Clodura
Sign Up

Sign Up for Free

Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.

Supercharge Your Prospecting

Supercharge Your Prospecting

Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.

Grow Your Business

Grow Your Business

Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.